Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 1, January-February, p. 103–110

Publication type: original article

Language: English

Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children

Anna Kofla-Dłubacz1,A,B,C,D,F, Małgorzata Matusiewicz2,C,D, Elżbieta Krzesiek1,B,E, Leszek Noga3,C, Barbara Iwańczak1,A,E,F

1 2nd Chair and Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland

2 Department of Medical Biochemistry, Wroclaw Medical University, Poland

3 Department of Pathophysiology, Wroclaw Medical University, Poland

Abstract

Objectives. The enhanced activity of matrix endopeptidases (MMPs) involved in the degradation of connective tissue has been noted in tissue samples from the digestive tract in inflammatory bowel disease (IBD), however sera concentrations of MMPs, a potential tool for diagnostic tests in IBD patients, have not been established so far. The goal of the studies was to evaluate the concentrations of MMP-3 and MMP-9, in the sera of children suffering from ulcerative colitis (UC) in relation to disease activity.
Material and Methods. The study was comprised of 31 children with UC (aged 3–18 years) and 37 children in the control group (aged 1–18 years). Disease activity was estimated using the Truelove-Witts scale. MMP-3 and -9 concentrations were determined using ELISA tests.
Results. Median MMP-3 concentrations were 18.4 ng/mL (95% CI: 12.5–24.3) for moderate and severe, 4.35 ng/mL (95% CI: 2.5–7.8) for the mild form of UC and 1.8 ng/mL (95% CI: 1.2–2.5) for the control group. Median MMP-9 concentrations were 18.0 ng/mL (95% CI: 2.83–36.6) for moderate and severe, 1.55 ng/mL (95% CI: 0.4–3.0) for the mild form of UC and 1.3 ng/mL (95% CI: 0.7–1.96) for the control group. Serum MMP-3 and MMP-9 concentrations in the moderate group were higher than those in the mild and control groups (p < 0.001). MMP-3 concentrations in the mild group also differed from those in the control group (p < 0.001). Among the parameters studied (MMP-3, MMP-9, CRP and ESR), MMP-3 had the highest discriminative value (AUC = 0.9, p < 0.001, sensitivity = 71%, specificity = 92%) in distinguishing patients with UC from healthy individuals.
Conclusion. Elevation of MMP-3 and MMP-9 concentrations along with the disease activity suggests the possibility of their application in the evaluation of the clinical activity of UC.

Key words

metalloproteinases, ulcerative colitis, children.

References (26)

  1. Meijer MJ, Mieremet-Ooms MA, van der Zon AM: Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn’s disease phenotype. Dig Liver Dis 2007, 39, 733–739.
  2. von Lampe B, Barthel B, Coupland SE: Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000, 47, 63–73.
  3. Medina C, Radomski MW: Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006, 318, 933–938.
  4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17, 464–516.
  5. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005, 41, 1–7.
  6. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2, 1041– –1048.
  7. Faveeuw C, Preece G, Ager A: Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. Blood 2001, 98, 688–695.
  8. Delclaux C, Delacourt C, D’Ortho MP: Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Resp Mol Cell Biol 1996, 14, 288–229.
  9. Di Sebastiano P, di Mola FF, Artese L: Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001, 63, 234–239.
  10. Naito Y, Takagi T, Kuroda M: An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflam Res 2004, 53, 462–468.
  11. Santana A, Medina C, Paz-Cabrera MC: Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006, 12, 6464–6472.
  12. Sykes AP, Bhogal R, Brampton C: The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzensulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999, 13, 1535–1542.
  13. Louis E, Ribbens C, Godon A: Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000, 120, 241–246.
  14. Gao Q, Meijer MJ, Kubben FJ: Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005, 37, 584–592.
  15. Manfredi MA, Zurakowski D, Rufo PA: Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008, 14, 1091–1096.
  16. Wang YD, Tan XY, Zhang K: Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm 2009, 275072. Epub 2009, 9.
  17. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B: Correlation of MMP-3 and MMP-9 with Crohn’s Disease Activity in Children. Dig Dis Sci 2012, 57, 706–712.
  18. Tezvergil-Mutluay A, Agee KA, Hoshika T: The requirement of zinc and calcium ions for functional MMP activity in demineralized dentin matrices. Dent Mater 2010, 26, 1059–1067.
  19. Kato MT, Leite AL, Hannas AR: Effect of iron on matrix metalloproteinase inhibition and on the prevention of dentine erosion. Caries Res 2010, 44, 309–316.
  20. Fagerberg UL, Lööf L, Myrdal U: Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005, 40, 450–455.
  21. Konikoff MR, Denson LA: Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12, 524–534.
  22. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006, 55, 426–431.
  23. Vermeire S, Van Assche G, Rutgeerts P: The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2, 580–586.
  24. Dollery CM, McEwan JR, Hanney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995, 77, 863–868.
  25. Tchetverikov I, Lard LR, DeGroot J: Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003, 62, 1094–1099.
  26. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression, Nature Rev Cancer 2002, 2, 161–174.